Terns Pharmaceuticals

Forecast & Rating10 analysts currently cover Terns Pharmaceuticals, with about 10.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $53.63, about 1.3% upside from the current price of $52.95. Price targets are fairly clustered, pointing to relatively aligned views. Historically, about 48.7% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Terns Pharmaceuticals's outlook. Data as of Apr 27, 2026; for reference only and not investment advice.